Send to

Choose Destination
See comment in PubMed Commons below
Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S27-32. doi: 10.1016/j.bbmt.2011.10.036.

Autologous stem cell transplantation and multiple myeloma cancer stem cells.

Author information

The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Division of Hematologic Malignancies, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.


It is well established that high-dose therapy (HDT) combined with autologous stem cell transplantation (ASCT) produces superior response rates and progression-free survival compared with conventional chemotherapy in patients with multiple myeloma (MM). Accordingly, MM currently represents the most common indication for ASCT. Despite these clinical improvements, the impact of ASCT on overall survival is unclear because the vast majority of patients eventually experience disease relapse and progression. The continual risk of relapse suggests that malignant cells resistant to HDT possess the clonogenic growth potential to mediate tumor regrowth, and in several diseases cancer stem cells (CSCs) have been identified that are both highly tumorigenic and resistant to standard anticancer approaches. Putative CSCs have been identified in MM, and their characterization may lead to the development of novel maintenance strategies that inhibit the production of new tumor cells, prevent disease relapse, and improve overall survival.

[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center